Texas 2017 - 85th Regular

Texas House Bill HB3256

Filed
 
Out of Senate Committee
 
Voted on by Senate
 
Governor Action
 
Bill Becomes Law
 

Caption

Relating to the establishment by certain counties and hospital districts of disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

Impact

If enacted, the bill would significantly influence state laws related to public health and safety, particularly concerning harmful practices related to drug use. It authorizes local governments and hospital districts to engage community and health organizations for the implementation of these pilot programs. The message is clear that by facilitating controlled access to clean needles and coordinating with local health authorities, Texas aims to mitigate public health issues resulting from intravenous drug use and its associated risks.

Summary

House Bill 3256 establishes a framework for disease control pilot programs in specified Texas counties, namely Bexar, Dallas, Harris, and Travis. The initiative aims to reduce the transmission of infectious diseases such as HIV, hepatitis B, and hepatitis C through the implementation of needle exchange programs. By enabling these pilot programs, the bill seeks to provide individuals with education and access to healthcare services, thereby addressing issues tied to substance abuse and public health risks associated with improperly disposed syringes.

Sentiment

The sentiment surrounding HB 3256 appears to be generally supportive among public health advocates who believe that harm reduction strategies, like needle exchange programs, are essential for decreasing the spread of infectious diseases. However, there might also exist contention from factions that view such initiatives as controversial, potentially fueling drug use rather than curbing it. Overall, the narrative from supporters emphasizes a compassionate approach to drug addiction as a public health issue, contrasting with opposition concerns regarding legitimacy and efficacy.

Contention

One notable point of contention is the authorization of fees for registration and the distribution of needles and syringes within the pilot programs. Proponents argue that these fees will help sustain the initiative through oversight costs and support law enforcement cooperation. Conversely, critics may see this as a barrier to accessing vital resources for vulnerable populations, potentially undermining the bill's objectives. The pilot programs are set to expire on September 1, 2027, which may raise questions about their long-term viability and funding structures.

Companion Bills

No companion bills found.

Similar Bills

TX HB65

Relating to disease control pilot programs to reduce the risk of certain communicable diseases; authorizing fees.

TX HB3238

Relating to disease control pilot programs to reduce the risk of certain communicable diseases; authorizing a fee.

TX SB1601

Relating to the establishment by certain counties and municipalities of disease control programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

TX HB1722

Relating to the establishment by certain counties and municipalities of disease control programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

TX HB1403

Relating to the establishment by certain counties and hospital districts of disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

TX HB3233

Relating to the establishment by certain counties and hospital districts of disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

TX SB2130

Relating to the establishment by certain counties and hospital districts of disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.

TX HB4342

Relating to the establishment by certain counties and hospital districts of disease control pilot programs to reduce the risk of certain infectious and communicable diseases; authorizing fees.